Inscopix has partnered with Brains On-Line, a Charles River Company, to advance the application of neural circuit mapping technology into the pharmaceutical contract research organization (CRO) market.
Inscopix technology enables direct readouts of brain circuit activity throughout disease progression and therapeutic intervention longitudinally in the same subject. This has led to significant advances in our understanding of the brain circuit activity underlying complex diseases, such as Parkinson's (PD), and Alzheimer's (AD). Charles River, together with Inscopix, will now provide objective and quantitative readouts of brain circuit health and dysfunction through circuit based drug screening assays. Together they are committed to advancing novel CNS therapies in early-stage research and drug screening.
"We are excited to partner with Inscopix to help further advance novel CNS therapies," said Arash Rassoulpour, PhD, Senior Director of Brains On-Line, a Charles River Company. "Their innovative brain mapping technology, coupled with our depth of scientific expertise, will bring us closer to finding treatments for patients."